McKesson Corporation (MCK) Cash Flow Statement

The OCF/NI ratio is highly volatile, ranging from -2.71 to 8.71 over the past ten quarters, indicating that net income is a poor proxy for cash generation in any given quarter. The negative readings in 2027Q1 and 2025Q3 coincide with large working capital outflows, suggesting that earnings quality is stable but cash conversion is heavily dependent on the timing of receivables and payables. Investors should focus on annualized cash conversion rather than quarterly figures to assess the underlying earnings quality.

The FCF margin has ranged from -2.7% to 8.2% over the last ten quarters, with the most recent quarter showing -0.3%. This volatility is primarily driven by working capital swings, as capex remains consistently low at around 0.1-0.2% of revenue. The underlying FCF generation appears stable when smoothed over multiple quarters, but the quarterly noise is significant and should be normalized for valuation purposes.

Capex has remained between $106 million and $189 million per quarter, which is remarkably low for a company with over $400 billion in annual revenue. This suggests that the company's competitive advantage is not tied to physical assets but rather to scale, relationships, and technology platforms. The low capital intensity allows for substantial free cash flow conversion, but it also implies that growth must come from working capital efficiency and acquisitions rather than organic capacity expansion.

The magnitude of working capital swings is enormous relative to net income, with changes often exceeding $2 billion in a single quarter. This reflects the company's position in the pharmaceutical supply chain, where it holds large receivables and payables. The negative working capital changes in 2027Q1 and 2025Q3 suggest that the company is funding its growth through supplier credit, but the timing of these swings is unpredictable. Investors should monitor the direction of working capital changes as a leading indicator of near-term cash flow.

The company has consistently repurchased shares, with quarterly buybacks ranging from $300 million to $2.7 billion, reflecting a strong commitment to returning capital to shareholders. However, acquisition activity is lumpy, with a notable $3.4 billion outflow in 2026Q1, likely related to strategic deals in the biopharma services space. The combination of buybacks and acquisitions suggests management is confident in its ability to deploy capital at attractive returns, but the pace of buybacks may need to moderate if acquisition opportunities continue.

The cumulative OCF/NI ratio of approximately 1.7x suggests that the company's earnings quality is high, with cash flows consistently outpacing reported net income. This divergence is likely due to non-cash charges such as depreciation and amortization, as well as favorable working capital dynamics. However, the quarterly volatility in OCF/NI (ranging from -2.71 to 8.71) highlights the importance of looking at longer-term trends rather than any single quarter. The cumulative data supports the view that McKesson's earnings are of high quality, but the timing of cash flows is inherently unpredictable.